Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegylated exenatide - Neuraly

Next Previous
X
Search
Drug Profile

Pegylated exenatide - Neuraly

Alternative Names: 4G - PEG exenatide - Neuraly; NLY-01; NLY01-AD; NLY01-D; NLY01-PD; Olaedin®; TLY 001

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuraly
  • Developer Neuraly; University of Pennsylvania
  • Class Antidementias; Antiglaucomas; Antihyperglycaemics; Antiparkinsonians; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Parkinson's disease; Type 2 diabetes mellitus
  • No development reported Glaucoma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Glaucoma in USA (Parenteral)
  • 27 Mar 2023 Efficacy and adverse events data from a phase II trial in Parkinson's Disease released by Neuraly
  • 19 Apr 2022 Neuraly completes enrolment in a phase II trial in Parkinson's disease (Early stage disease, Treatment naive) in USA and Canada (SC, injection) (NCT04154072)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top